Graviton Bioscience

Graviton Bioscience is a biotechnology startup that aims to cure diseases through restored homeostasis. Founded in 2023 and headquartered in the United States, their focus lies in developing therapies that inhibit Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2), in addition to other therapeutic compounds. Their recent achievement includes securing a $25.00M corporate round investment on 01 February 2024, with Sanofi being the lead investor. This latest investment not only validates the potential of Graviton Bioscience but also paves the way for further advancements in their quest to revolutionize disease treatment through innovative biotechnological approaches. With their pioneering research and strong investor backing, Graviton Bioscience is poised to make significant strides in the biotechnology landscape, offering promising prospects for potential venture capital involvement.